GlassScriptPhysician profile
Abbas Alshami
NPI 1336600378
$20,825.66
in general payments reported to CMS, 2019-2025
26 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $278 · 2023: $631 · 2024: $1,927 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $11K · Food and Beverage: $5,143 · Travel and Lodging: $3,963 · Education: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $11,000.00 |
| Food and Beverage | $5,142.90 |
| Travel and Lodging | $3,963.22 |
| Education | $441.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $9,143.82 | 2025 | Corevalve Evolut R, Pulseselect, Selectsecure |
| Abbott Laboratories | $6,339.65 | 2023-2025 | Assurity, Tacticath, Aveir |
| Boston Scientific Corporation | $2,726.92 | 2024-2025 | General - Therapies, General - Vascular Access |
| Shockwave Medical, INC | $688.79 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $399.15 | 2022-2025 | Lifevest |
| Pfizer INC. | $214.55 | 2022-2025 | |
| Acist Medical Systems, INC. | $165.42 | 2022 | |
| Edwards Lifesciences Corporation | $162.87 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Orapharma, A Division of Bausch Health US, LLC | $147.90 | 2024 | |
| Abiomed | $124.13 | 2023-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $104.39 | 2022-2025 | Eliquis, Camzyos |
| Chiesi USA, INC. | $101.61 | 2023-2025 | Kengreal |
| Astrazeneca Pharmaceuticals LP | $82.44 | 2024-2025 | Wainua |
| Novartis Pharmaceuticals Corporation | $76.66 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.40 | 2023-2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $48.75 | 2025 | Carto 3 |
| Scpharmaceuticals INC. | $45.41 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $33.72 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $33.18 | 2023 | Arcalyst |
| Procyrion, INC. | $23.15 | 2024 | |
| Daxor Corporation | $20.42 | 2023 | Bva-100 |
| Lantheus Medical Imaging, INC. | $17.48 | 2024 | |
| Ancora Heart, INC. | $17.42 | 2024 | Accucinch |
| Janssen Pharmaceuticals, INC | $17.00 | 2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $14.22 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbas Alshami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.